Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 18/20 | 0.54 |
| ▸ | PDE4A | P27815 | 13/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4207820 | 0.88 | CYP2C9 (0.70) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4207376 | 0.86 | CYP2C9 (0.65) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4217368 | 0.84 | CYP2C9 (0.76) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4215908 | 0.78 | CYP2C9 (0.68) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL13947429 | 0.78 | CYP2C9 (0.60) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4206686 | 0.75 | CYP2C9 (0.68) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4207434 | 0.75 | CYP2C9 (0.79) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4216185 | 0.75 | CYP2C9 (0.66) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4216204 | 0.74 | CYP2C9 (0.69) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4200336 | 0.74 | CYP2C9 (0.80) | CYP2C9PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060223850-A1 | 8-(3-Biaryl)phenylquinoline phosphodiesterase-4 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2006-10-05 | — | — | US | claimed |
| US-7482456-B2 | antiasthmatic; antiinflammatory; minimal side effects; 8-(3-{2-(3-chlorophenyl)-4-[4-(methylsulfonyl)phenyl]-1,3-thiazol-5-yl}phenyl)-6-[1-methyl-1-(methylsulfonyl)ethyl]quinoline; 2-[5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-4-pyridin-3-yl-1,3-thiazol-2-yl]propan-2-ol | MERCK FROSST CANADA | 2009-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223850-A1 | 8-(3-Biaryl)phenylquinoline phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE3B | CYP2C9 354/4885PDE4A 1/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.